ArticleEvidence-based dentistry2015
Maternal xylitol and mutans streptococci transmission.
Article in Evidence-based dentistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 5 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
- Comment on
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
data sourcesPubMed, EMBASE, SCOPUS, Cochrane Central Register of Controlled Trials databases and the ClinicalTrials.gov registry were searched with related articles'. Experts were contacted and a manual search of reference lists was undertaken. STUDY SELECTION: Randomised or quasi-randomised controlled trials that evaluated the maternal use of xylitol gum on Mutans Streptococci (MS) colonisation in infants. DATA EXTRACTION AND SYNTHESIS: Two independent reviewers performed data extraction with a third reviewer asked to resolve any disagreements. Cochrane risk of bias tool was used to assess the quality of studies. Two reviewers independently appraised the methodological quality. The primary outcome measure was presence of MS in the saliva or plaque of infants, with the secondary outcome measure being occurrence of dental decay.
results11 studies published between 2000 and 2012 involving a total of 601 patients were included. Sample sizes ranged from 60 to 195 and the daily dose of xylitol consumption ranged from 1.95g to 5.28g. Follow-up ranged from six months to 120 months. There was a significant difference between the two groups, with infants in the control group experiencing greater incidences of MS in their plaque or saliva. Risk ratios were 0.44 (95% CI: 0.08-2.40) at 6-9 months, 0.54 (95% CI: 0.39-0.73) at 12-18 months, 0.60 (95% CI: 0.34-1.08) at 24 months, 0.56 (95% CI: 0.40-0.79) at 36 months and 0.61 (95% CI: 0.48-0.76) at 60 months. Caries data could not be pooled.
conclusionsXylitol consumption by mothers with high MS levels was associated with a significant reduction in the mother-to-child transmission of salivary MS. These findings are based on evidence that may have suffered from biases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.